Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers
COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.
Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages.
Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio.
America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.
"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines."
Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients."
"As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter.
"Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said.
Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans.
Contacts :
Hikma Pharmaceuticals PLC
Investors
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
Media
Steven Weiss
US Communications
+1 732 788 8279
About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines-302493824.html
SOURCE Hikma Pharmaceuticals USA Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Warren Buffett Is Giving Away $6 Billion — Here's Who Is Getting It
Warren Buffett, a billionaire investor and philanthropist, announced he's donating $6 billion to five charities The charities that will receive the funds include his three children's charities and the Bill & Melinda Gates Foundation Trust, whom he was a trustee with from 2006 to 2021 Buffett's estimated net worth is $152 billionWarren Buffett is giving away $6 billion — his biggest donation in almost two decades — to five charities by the end of the month. The chairman and CEO of Berkshire Hathaway and philanthropist, 94, announced in a press release on Saturday, June 28, that he is giving away $6 billion in Berkshire Hathaway shares to the Bill & Melinda Gates Foundation Trust and four other charities. The Bill & Melinda Gates Foundation Trust is one charity that Buffet has worked closely with over the years, as he has served as a trustee for the charity between 2006 and 2021. According to the trust's website, Buffett has pledged a total of $36 billion to the charity through 2022. Another charity that will be receiving a portion of the $6 billion is the charity he started with his first wife, the Susan Thompson Buffett Foundation, which is focused on family planning and reproductive health. The Sherwood Foundation, Howard G. Buffett Foundation and NoVo Foundation, which were founded by his three adult children Susan, 72, Howard, 70, and Peter, 67, respectively, will also get a portion of the funds. The donations will be delivered to the charities on June 30. He converted over 8,000 Class A shares and over 12 million Class B shares of Berkshire Hathaway shares in order to make the donation, which is his largest donation since 2006, according to Forbes. 'The mathematics of the lifetime commitments to the five foundations are interesting,' Buffet said in a statement. 'The schedule for annual grants was made on June 26, 2006, and has since been supplemented by significant grants to four of the five recipients.' 'When originally made, I owned 474,998 Berkshire A shares worth about $43 billion and those shares represented more than 98% of my net worth. I have converted A shares into B shares before making contributions,' he added. Buffett, whose estimated net worth is $152 billion, also shared in his statement that upon his death, 'about 99½%' of his estate is 'destined for philanthropic usage,' per his will. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Last year it was reported that the Nebraska businessman planned to donate his fortune to a charitable trust after his death, according to the Associated Press. His three children would be in charge of the trust and have 10 years to allocate the money to charities of their choice. 'It's not so easy to give away money if you want to do it smart, if you want to be intelligent about it,' Howard told the AP in September 2024. 'It's pretty amazing that he's giving us this opportunity.' He also plans to continue to donate to the Gates Foundation and to his family's charities annually until his death, per AP. Read the original article on People Inicia sesión para acceder a tu portafolio
TechCrunch
30 minutes ago
- TechCrunch
Authors call on publishers to limit their use of AI
In Brief An open letter from authors including Lauren Groff, Lev Grossman, R.F. Kuang, Dennis Lehane, and Geoffrey Maguire calls on book publishers to pledge to limit their use of AI tools, for example by committing to only hire human audiobook narrators. The letter argues that authors' work has been 'stolen' by AI companies: 'Rather than paying writers a small percentage of the money our work makes for them, someone else will be paid for a technology built on our unpaid labor.' Among other commitments, the authors call for publishers to 'make a pledge that they will never release books that were created by machine' and 'not replace their human staff with AI tools or degrade their positions into AI monitors.' While the initial letter was signed by an already impressive list of writers, NPR reports that another 1,100 signatures were added in the 24 hours after it was initially published. Authors are also suing tech companies over using their books to train AI models, but federal judges dealt significant blows to those lawsuits earlier this week.
Yahoo
37 minutes ago
- Yahoo
Visa Inc. (V): 'This Is Your Chance' To Buy, Says Jim Cramer
Visa Inc. (NYSE:V) is one of the . Visa Inc. (NYSE:V) is one of the largest financial technology and payment platform providers in the US. Its shares have gained 9.7% year-to-date after facing a tumultuous ride on the stock market. Visa Inc. (NYSE:V)'s stock has lost 5.6% in June after regaining some ground from an earlier 7.3% dip. The shares dipped as the firm suffered in the aftermath of the Senate passing new legislation. This bill introduced federal oversight for stablecoins and led to speculation that retailers could shift to digital currencies and remove the firm from the payments legislation. Commenting on the risk-off sentiment, Cramer shared: 'We've gotta keep going on this Visa. . . Because a lot of our viewers think that these companies are really at risk. I actually think this is your chance to buy them. They're always at risk and they always win.' A financial analyst reviewing stock prices on a graph with a positive outlook. Cramer discussed these trends about Visa Inc. (NYSE:V) later during the day in Mad Money: 'Over the past couple of weeks, Visa and MasterCard, two of my favorite companies, have pulled back sharply from their all-time highs. Wall Street's suddenly worried about the whole payments industry, might be threatened by advances in crypto, especially now that Congress looks like it'll pass its GENIUS Act, which establishes a framework for regulating Stablecoins. Visa fell over 10% from its high, set on June 11, to its low last Friday… This morning I spoke with Visa CEO, Ryan McInerney, and Ryan told me, I think, a story which made me feel like that, that you'd be nuts to be in this, frankly.' While we acknowledge the potential of V as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
